Lupin Share Price in Focus After Launching New COPD Inhaler Formoflo-G

Written by: Team Angel OneUpdated on: 6 Oct 2026, 4:59 pm IST

Lupin has launched Formoflo-G MDI in India, a three-drug inhaler for the long-term treatment of moderate to severe COPD.

Lupin has launched Formoflo-G MDI in India after receiving approval from the Drug Controller General of India (DCGI). The company describes it as the world's first fixed-dose triple combination metered-dose inhaler for COPD.

Three Medicines in One Inhaler

Formoflo-G MDI brings the Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate together in a single inhaler and is available as a twice-daily fixed dose.

Lupin said the product is aimed at patients living with COPD in India, where more than 55 million people are affected by the condition.

Lupin Adds to Its Respiratory Portfolio

Lupin already has a sizeable presence in the respiratory medicines market. The company was ranked second in India's respiratory therapy segment in March 2026, according to IQVIA data cited in the release.

The company said the new inhaler adds another treatment option for COPD patients and doctors.

As of October 06, 2026, at 10:59 AM, Lupin share price was trading at ₹2,021.20 per share, reflecting a 0.51% surge from the previous trading session.

Conclusion

Lupin has added Formoflo-G MDI to its India respiratory portfolio after receiving DCGI approval. The inhaler combines three medicines and is meant for long-term treatment of moderate to severe COPD, while the company continues to have a large presence in India's respiratory medicines market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Oct 6, 2026, 11:29 AM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More